Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Beyond Meat Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while Beyond Meat Inc trades at $0.4 (market cap $215.41M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 23.5× Beyond Meat Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BYND | |
|---|---|---|
Market Cap | $5.07B | $215.41M |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $3.62 |
52-Week Low | $20.06 | $0.42 |
Enterprise Value | $4.19B | $455.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Beyond Meat (BYND) trades at $0.52, down 3.29% amid bearish technical signals and recent reverse stock split. The company shows mixed fundamentals with revenue declining from $419M in 2022 to $275M in 2025, though net income turned positive at $178M in 2025 with a 64.6% margin. Technical indicators show bearish momentum with moving averages signaling sell and ADX confirming strong downtrend, while RSI remains neutral. Recent news highlights stock collapse to all-time lows following the 30:1 reverse split announcement in August 2026.
Investment outlook remains highly risky with 57% analyst sell ratings and persistent cash burn from operations. While valuation ratios appear attractive (P/S 0.61, EV/EBITDA 1.28), declining revenue and negative operating cash flow (-$145M in 2025) challenge sustainability. The turnaround strategy focusing on international expansion faces execution risks amid competitive pressures and consumer demand uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
